Lilly, partner sue Lupin over generic testosterone
Indianapolis-based Eli Lilly and Co. and Acrux DDS Pty Ltd. have filed a lawsuit against Lupin Pharmaceuticals Inc. for alleged infringement of patents that cover the testosterone treatment Axiron.
Indianapolis-based Eli Lilly and Co. and Acrux DDS Pty Ltd. have filed a lawsuit against Lupin Pharmaceuticals Inc. for alleged infringement of patents that cover the testosterone treatment Axiron.
The drug, known as necitumumab, improved patients’ overall chances of survival, yet people taking the medicine also experienced more risk, Food and Drug Administration staff said in a report Tuesday.
With Aetna Inc. and Humana Inc. agreeing to a $37 billion merger, pressure is mounting on the other major health insurers, including Cigna Corp. and Anthem Inc., to make their own deals.
Aetna Inc. agreed to buy Humana Inc., the second-largest provider of private Medicare insurance, for $37 billion in cash and stock to broaden its health-care coverage.
Michael A. Byers’ Tooth Bank is one of a tiny group of U.S. companies catering to the latest iteration of stem cell therapy: harvesting stem cells from the pulp inside baby teeth and extracted wisdom teeth, then culturing, freezing and storing them at a cryostorage facility for later use.
Patients from around the country have filed 100 lawsuits against Bloomington-based Cook, alleging that some of its blood-clot filters have broken apart, moved or poked through the blood vessel where they are implanted.
The Indianapolis-based hospital system has agreed to pay $20.3 million to settle claims that it overbilled the Medicare and Medicaid programs.
Anthem Inc.’s proposed $47 billion buyout of Cigna Corp. is the latest example of corporate deals that get hung up over executive egos and turf battles. For example, Anthem CEO Joe Swedish wants to lead the merged firm, to the chagrin of Cigna’s CEO.
Wellness company On Target Health LLC, which one year ago launched a program to help overweight workers lose fat but not muscle, is seeing strong results from its first two clients.
Eli Lilly and Co. received some European legal backing for its top product, the lung cancer treatment Alimta, on Thursday when a British court upheld a patent protecting a vitamin regimen administered with the drug.
Eli Lilly and Co. has been ordered to face claims it misled consumers about “brain zaps” and other withdrawal side effects tied to its antidepressant Cymbalta in the first cases slated to be heard by juries.
The Indiana-based company has taken the name Zimmer Biomet Holdings Inc. and will trade under the ticker symbol to "ZBH" on Monday. Zimmer Holdings Inc. agreed to buy privately-held Biomet in April 2014.
About 160,000 low- and moderate-income Indiana residents could lose health insurance premium subsidies provided under the Affordable Care Act if the U.S. Supreme Court rules them illegal, two groups estimated Tuesday.
In a new scoring system for oncology drugs, a leading group of U.S. cancer doctors awarded a zero for overall benefit to a regimen featuring Alimta, Eli Lilly and Co.’s top-selling product.
After years of pipeline failures, Eli Lilly and Co. is on a bit of a hot streak. This month alone, the Indianapolis-based drugmaker has reported positive results from clinical trials of four experimental drugs.
Kem Hawkins, who has been president of Cook Group Inc. since 2001, will retire on July 1. He will be replaced by Pete Yonkman, who since 2013 has been president of Cook Medical, the Cook subsidiary that makes medical devices.
The acquisition lets Hill-Rom, a maker of hospital supplies for wound care and respiratory health, delve further into the market for diagnostic supplies for physicians and emergency responders
The biggest U.S. providers—UnitedHealth Group Inc., Anthem Inc., Aetna Inc., Cigna Corp. and Humana Inc.—are all looking at possible combinations. Indianapolis-based Anthem is considering a takeover of Cigna or Humana, a person familiar with the matter said.
Anthem Inc. has made a buyout offer to rival health insurer Cigna Corp. for $45 billion, The Wall Street Journal reported Monday. That price would make the deal the largest health insurance merger in U.S. history.
Intarcia Therapeutics Inc. is betting its matchstick-size pump could take market share from Eli Lilly and Co., AstraZeneca Plc and Novo Nordisk A/S.